GENERIS

AMERICAN BIOMANUFACTURING SUMMIT 2021

APRIL 27-29, 2021

biomanamerica.com

TOMORROW'S CONNECTION TODAY

Designing a new future for manufacturing, quality and supply chain leaders

+1-416-298-7005
info@generisgp.com

PROGRAM

PROGRAM · DAY 1

APRIL 27, 2021

10:00 am – 10:30 am EST

LOG-IN AND WELCOME

10:35 am – 10:45 am EST

CHAIR'S OPENING REMARKS

CHRIS MCDONALD
SVP and Global Head, Manufacturing
Kite Pharma

10:45 am – 11:20 am EST

OPENING KEYNOTES

LARS DREESMANN, PH.D.
President and Site Head
Boehringer Ingelheim Fremont, Inc.

JEFFREY BAKER
Deputy Director, Office of Biotechnology Products, CDER, FDA at CDER
FDA

LEVERAGING FLEXIBLE NETWORKS, QUALITY CULTURE AND CUTTING EDGE INNOVATION

- How biomanufacturing can address the dichotomy of small volume precision medicines and high volume blockbuster drugs
- Building flexible global manufacturing networks to meet our industry's evolving needs
- Leveraging cutting-edge innovation to maximize process intensification and augment flexibility
- Creating high-performance teams and building and maintaining a culture of quality, reliability and innovation as key differentiator and foundation for continued success

DISCUSS, DEPLOY, OR DEFER: NEW TECHNOLOGIES IN REAL WORLD BIOPHARMACEUTICAL MANUFACTURING

- Examining the landscape for new technologies in domestic biotech
- Unravelling the science behind regulatory CMC challenges associated with new product development and approval
- Maintaining a commitment to continuous improvement in biopharmaceutical manufacturing

11:25 am – 12:00 pm EST

PLENARY

ANGELO STRACQUATANIO
CEO and Co-Founder
Apprentice.io

THE RAPID ADOPTION OF INTELLIGENT MANUFACTURING AND PHARMA 4.0 DURING COVID

- How Apprentice solutions helped the world's leading life science organizations navigate through the COVID-19 pandemic
- Incorporating AI, AR and Pharma 4.0 principles to help you scale faster
- Small/large molecule and cell & gene therapy use cases
- How to easily leverage the content you already have to make deployment fast and easy

12:05 pm – 12:45 pm EST

PRE-ARRANGED 1-2-1 BUSINESS MEETINGS AND NETWORKING

12:50 pm – 1:30 pm EST

LUNCH & LEARN ROUNDTABLE DISCUSSIONS

Benefit from additional learning by joining a moderated roundtable discussion on pressing issues in the industry. Registration is required, and attendance is limited. Choose from:

CAROLINA VALOYES
Head, Corporate Quality Systems
Boehringer Ingelheim, Inc.

DRIVING DATA INTEGRITY ACROSS MULTIPLE ORGANIZATIONS

PÄR ALMHEM
Director, Business Development
KeyPlants

RAPID AND COST EFFECTIVE DEPLOYMENT OF MODULAR BIOMANUFACTURING FACILITIES

CARL RADOSEVICH
Senior Manager, Scientific Applications and Collaborations
PHC Corporation of North America

SCALING UP YOUR CELL CULTURE

RAHUL KAUSHIK
VP and Head, Antibody/Protein Process Development and Manufacturing
FibroGen

EMBRACING TECHNOLOGY TO IMPROVE THE WAY YOU GATHER, ANALYZE, REPORT AND SHARE PROCESS DATA ACROSS MANUFACTURING NETWORKS

BRENT LIEFFERS
Senior Director, Operations
Singota

AVOIDING DELAYS CAUSED BY THE FILL/FINISH BOTTLENECK WHEN GETTING YOUR PRODUCT INTO THE CLINIC

SCOTT WHYTE
Chief Digital Officer
AeroSafe

TRENDS IN SUPPLY CHAIN ACCELERATED BY COVID-19 AND IMPLICATIONS BEYOND

1:35 pm – 2:10 pm EST

WORKSHOPS

MANUFACTURING AND TECHNOLOGY

THOMAS GERVAIS
Head, Manufacturing, Science, and Technology (MSAT)
Samsung Biologics

CONTINUOUS MANUFACTURING TECHNOLOGY TO EXISTING PROCESS: CHALLENGES AND ADVANTAGES OF IMPLEMENTING N-1 PERFUSION TECHNOLOGY

- Impact of continuous technology on tech transfer and process scale-up
- Key considerations and challenges in N-1 perfusion to meet reduced cell culture duration and higher protein titers in the overall product yield
- Real case: Before vs After implementing N-1 technology
- Preparing for next plan for continuous process intensification

QUALITY AND COMPLIANCE

ANH VO, M.A., ACC
Senior Principal
ALULA

DANIELLE GEISSLER, PH.D.
Senior Principal
ALULA

HOW TO COMBAT UNCERTAINTY FATIGUE AND DRIVE ENGAGEMENT

- Sharing strategies to help teams overcome "uncertainty" fatigue
- Identifying how uncertainty fatigue impacts engagement
- Highlighting steps to take to shape a high-performance culture

SUPPLY CHAIN AND LOGISTICS

MICHAEL DELLORTO
VP, Business Development
MNX Global Logistics

LEVERAGING YOUR CLINICAL SHIPMENT "BIG DATA" TO IMPROVE DECISION MAKING

- Why simplicity and visibility on every piece of the end-to-end logistics process is the key to success
- How collaborative partnerships and a laser focus on quality ensures trial and commercial success
- MNX technology showcase

2:15 pm – 2:55 pm EST

PRE-ARRANGED 1-2-1 BUSINESS MEETINGS AND NETWORKING

3:00 pm – 3:35 pm EST

SESSIONS

MANUFACTURING AND TECHNOLOGY

ROHINI DESHPANDE, PH.D.
VP, Drug Substance Technologies, Process Development and Massachusetts Site Head
Amgen

NEXT GENERATION BIOMANUFACTURING: A JOURNEY

- Discussing the advent of immuno-oncology targets, lower volume high potency molecules and multi specifics
- Sharing the role new manufacturing technology in overcoming the ongoing challenges currently facing the sector (cornerstone technologies for MoF-ATF, single use, media, harvest and downstream becoming critical to next generation manufacturing)
- Why biomanufacturing needs will be different and challenges the adaptation of manufacturing capabilities to meet the needs of the diverse pipeline
- Future considerations on manufacturing innovation

QUALITY AND COMPLIANCE

KIM BURSON, PH.D.
Head, Quality Assurance and Quality Control
Denali Therapeutics

ESTABLISHING A QUALITY PARTNERSHIP WITH YOUR SUPPLIERS AND OUTSOURCED CONTRACT MANUFACTURING/TESTING SITES

- Sharing your quality vision and responsibilities with your outsourced partners
- Establishing and negotiating quality agreements with partners in your network
- Navigating the challenges of auditing outsourced partners during a pandemic
- Analyzing the performance of outsourced partners: What tools and processes can be applied?

SUPPLY CHAIN AND LOGISTICS

CRAIG MALZAHN
VP, Manufacturing and Supply Chain
REGENXBIO

BUILDING A FLEXIBLE GENE THERAPY SUPPLY CHAIN TO ACCELERATE DRUG DEVELOPMENT

- Strategic principles to guide decision making
- Manufacturing optionality for a broad pipeline
- Scalable technology right-sized with customer demand
- Accelerating drug development with platform processes

3:35 pm – 4:35 pm EST

EXPO HALL NETWORKING

PROGRAM · DAY 2

APRIL 28, 2021

9:45 am – 9:55 am EST

LOG-IN AND WELCOME

10:00 am – 10:50 am EST

EMPOWER HOUR

TERESA RODÓ
EVP and Head, Global Healthcare Operations
Merck KGaA, Darmstadt, Germany

GAYLE GIRONDA
VP, Human Resources
Bristol-Myers Squibb

ROBERT BOTTOME
VP, Global Supply Chain
BioMarin Pharmaceuticals Inc.

GISSELLE PEREZ
Head, Global Diversity, Equity & Inclusion, and People Relations
Biogen

VICKY VERONNEAU
SVP, Quality, Novartis Gene Therapies
Novartis

JORDYNE BLAISE
Director, Diversity, Equity and Inclusion
bluebird bio

DIVERSITY AND INCLUSION ROUNDTABLE

We invite attendees to network at the Diversity and Inclusion Roundtable with discussions from inspirational leaders in manufacturing, supply chain, quality and more.

10:55 am – 11:05 am EST

CHAIR'S OPENING REMARKS

CHRIS MCDONALD
SVP and Global Head, Manufacturing
Kite Pharma

11:05 am – 11:40 am EST

OPENING KEYNOTES

JENS VOGEL
SVP and Global Head, Biotech
Bayer Pharmaceuticals

PATRICK Y. YANG, PH.D.
Executive Vice Chairman and Co-Founder, National Resilience, Inc., Chairman/Co-Founder, Acepodia, Inc., Executive Chairman, AltruBio, Inc., Former EVP
Juno, Roche and Genentech

PLANNING FOR THE FUTURE OF BIOMANUFACTURING: PAVING THE WAY FOR SUCCESSFUL INDUSTRIALIZATION OF NEW THERAPEUTIC MODALITIES

- How mRNA technology as well as cell and gene therapies promise to revolutionize medicine and may enable curative approaches for hard to treat diseases
- Why open innovation and external partnering in discovery and product innovation works – for both innovators and mature biopharma companies
- What are the biggest challenge of bringing these therapies to patients globally – stepping up the pace of adoption of new technologies, current industry limitations in CMC capabilities and capacity bottlenecks
- Delivering success in industrializing cell and gene therapies requires vision, leadership, diverse talent, the right organizational set-up and the right culture
- Case study: Discussing how Bayer is leveraging its core strengths in advanced manufacturing of difficult to make biologics in defining its technological approaches, including process integration, intensification, automation and digitalization which form the basis for creating our next generation cell and gene manufacturing platforms

BIOMANUFACTURING 2031: REFLECTING ON THE PAST AND SETTING GOALS FOR THE NEXT DECADE OF INNOVATION

- What does biomanufacturing innovation look like in the post-COVID economy?
- Discussing an industry in transition and what's on the horizon
- Being a patient-focused business leader that embraces technology
- Placing an emphasis on Operational Excellence and sustainable growth
- Investing in our science, facilities and commercial capabilities to deliver better outcomes
- Creating innovative medicines to treat patients and protect public health around the world

11:45 am – 12:20 pm EST

PLENARY

Merck KGaA
Darmstadt, Germany

TERESA RODÓ
EVP and Head, Global Healthcare Operations
Merck KGaA, Darmstadt, Germany

INVESTING IN AGILITY, RESILIENCY, AND COLLABORATION DURING THE COVID-19 PANDEMIC

- Prioritizing the health, safety and well-being of employees
- Ensuring the continuity of operations and continuing to build for the future
- Contributing to the fight against COVID-19
- Building on the learnings from the COVID-19 crisis

12:25 pm – 1:05 pm EST

PRE-ARRANGED 1-2-1 BUSINESS MEETINGS AND NETWORKING

1:10 pm – 1:50 pm EST

LUNCH & LEARN ROUNDTABLE DISCUSSIONS

Benefit from additional learning by joining a moderated roundtable discussion on pressing issues in the industry. Registration is required, and attendance is limited. Choose from:

CAI

NATHAN TEMPLE
C&Q Global Business Area Lead
CAI

RAPID RESPONSE MANUFACTURING

MNX GLOBAL LOGISTICS

MICHAEL DELLORTO
VP, Business Development
MNX Global Logistics

CELLULAR THERAPY SHIPPING BEST PRACTICES & SUCCESS STORIES

Bionova Scientific

ERIC FULMER
VP, Quality and Compliance
Bionova Scientific

ESTABLISHING A STATE-OF-THE-ART CELL CULTURE FACILITY: CONSIDERATIONS IN DESIGN, IMPLEMENTATION, VALIDATION/QUALIFICATION, OPERATIONS, COMPLIANCE

aizon

ANDY ALASSO
SVP, Product Management
Aizon

INDUSTRIALIZING ARTIFICIAL INTELLIGENCE IN BIOPHARMA MANUFACTURING FOR PREDICTIVE OPERATIONAL INSIGHTS AND BUSINESS VALUE REALIZATION

Polyplus transfection

JULIEN DEPOLLIER
Director, Strategic Partnerships
Polyplus-transfection

HOW TO IMPROVE VIRAL TITERS BY OPTIMIZING YOUR UPSTREAM PROCESS?

Boston ANALYTICAL

MIKE MOLLOY
Technical Director
Boston Analytical

HOW TO ENGAGE THE EXPERTISE AVAILABLE AT A DEDICATED ANALYTICAL LAB AND STAY NIMBLE

aventior

DOMINIC MANCINI
Senior Manager, Data Systems and Analytics
bluebird bio

AN AI-ASSISTED APPROACH TO DIGITIZE PAPER BATCH RECORDS AND IMPROVE OPERATIONAL OVERSIGHT

1:55 pm – 2:30 pm EST

WORKSHOPS

MANUFACTURING AND TECHNOLOGY

CHRIS PROCYSHYN
General Manager
Vanrx, a Cytiva Company

YES, WE CAN DO THINGS QUICKLY IN DRUG PRODUCT. HERE IS HOW YOU CAN MAKE IT HAPPEN.

- How the past year has proven that innovations in drug product technology can be implemented faster
- Why maintaining the status quo now poses increased strategic and production risks
- How new production and facility technologies have helped manufacturing leaders bring drug products to patients faster and with less risk

QUALITY AND COMPLIANCE

CHRISTOPHER MURPHY
VP & GM, Viral Vector Services
Thermo Fisher Scientific

BUILDING VIRAL VECTOR CAPACITY AND CAPABILITIES TO REALIZE THE PROMISE OF GENE THERAPIES

- Current overview on Capacity
- Innovation and Technology Updates
- An in-depth view of our Capabilities
- People: our most valuable resource

SUPPLY CHAIN AND LOGISTICS

SANDRA ANDERSON
SVP, Commercialization and Strategy
Innomar Strategies

DECISIONS MANUFACTURERS SHOULD CONSIDER WHEN LAUNCHING INTERNATIONALLY

- Overview of the landscape and process for commercializing pharmaceutical products
- Considerations for each stage of launching a specialty pharmaceutical or biologic: pre-development, development, pre-launch and launch
- Case study: Illustrating how companies can successfully launch new therapies in Canada
  - The importance of generating Real World Evidence, and an update on how Health Canada is engaging on evidence generation from a regulatory perspective
  - Unique Canadian market dynamics, commercialization considerations and lessons learned
  - Discussion of the supply chain and logistic models for consideration at launch
- Insights and considerations on commercial, regulatory, market access and payer opportunities

2:35 pm – 3:15 pm EST

PRE-ARRANGED 1-2-1 BUSINESS MEETINGS AND NETWORKING

3:20 pm – 3:55 pm EST

SESSIONS

MANUFACTURING AND TECHNOLOGY

DEREK ADAMS, PH.D.
Chief Technology and Manufacturing Officer
bluebird bio

DEVELOPING MANUFACTURING PRACTICES AT A RAPID PACE FOR THE CREATION OF CELL AND GENE THERAPIES

- Exploring recent and significant milestones in the CAR-T space and beyond
- Reviewing developments at bluebird bio to advance these therapies through to commercialization
- Examining the technical, clinical, and manufacturing challenges involved in live modality therapies
- Exploring evolving FDA guidelines on live modality therapies
- How can the industry contribute more to the future of our regulatory environment?
- Finding ways to reduce costs and improve patient access

QUALITY AND COMPLIANCE

CHARLES L. COONEY, PH.D.
Professor, Chemical Engineering; Director, Center for Technological Innovation
MIT - Massachusetts Institute of Technology

THE FUTURE FOR BIOMANUFACTURING: INTENSIFICATION, INTEGRATION AND INTERROGATION

- Understanding how to best address patients needs
- Managing quality, speed, cost and flexibility
- Fulfilling the business case

SUPPLY CHAIN AND LOGISTICS

JEFF DAVIS
Executive Director, Clinical Supply Center and Digital Technologies
Genentech, A Member of the Roche Group

REIMAGINING GLOBAL MANUFACTURING: FOR NOW AND FOR THE FUTURE

- Creating a manufacturing network for the future of personalized medicines
- How manufacturing standards can create resilience in global supply chains
- Leveraging Industry 4.0 solutions to deliver innovative medicines to patients
- Building an organizational culture of agility, resiliency, and sustainability
- What new practices and tools should we retain after the pandemic subsides?
- Offering real-world examples from Genentech's newest manufacturing facility

4:00 pm – 5:00 pm EST

EXPO HALL NETWORKING

PROGRAM · DAY 3

APRIL 29, 2021

9:45 am – 10:00 am EST

LOG-IN AND WELCOME

10:00 am – 10:50 am EST

EMPOWER HOUR

FANZIA MOHAMMED
VP and Global Head, Quality Systems and Quality Management
Genentech

LISA WYMAN
SVP, Technical Operations and Quality
Acceleron Pharma Inc.

EVA MARTINS
Global Head, Innovation and Digital Commercial Transformation
Novartis

HEIKE ROEDER
VP, Lead Digital Transformation QMS
Bayer AG

SILKE MOHL
VP and Head, Technical Development
Roche

ANNE MARIE DE JONGE SCHUERMANS, PH.D.
SVP, Global Technical Operations, and Executive Committee Member
Sobi Orphan Biovitrum AB

WOMEN IN LEADERSHIP ROUNDTABLE

We invite our attendees to network at the Women in Leadership Roundtable with discussion from inspirational leaders in manufacturing, quality and supply chain.

SPONSORED BY:
Danielle Geissler, Ph.D., Senior Principal

BREAKFAST BRIEFS

KENNY NG
Regional Director, Americas
Singapore Economic Development Board

SUPPLY CHAIN RESILIENCY THROUGH DIVERSIFICATION: LESSONS FROM COVID, AND HOW BIOPHARMACEUTICAL COMPANIES ARE INCREASING SUPPLY CHAIN RESILIENCY THROUGH SUPPLY CHAIN DIVERSIFICATION

10:50 am – 11:00 am EST

CHAIR'S OPENING REMARKS

CHRIS MCDONALD
SVP and Global Head, Manufacturing
Kite Pharma

11:05 am – 11:40 am EST

OPENING KEYNOTES

JOYDEEP GANGULY
SVP, Operations
Gilead Sciences

MICHELANGELO CANZONERI, PH.D.
Global Head, Digital and Data, Healthcare
Merck KGaA, Darmstadt, Germany

POST-COVID CONSIDERATIONS: RE-IMAGINING THE WAY WE WORK

- How COVID-19 has affected the changing landscape of biomanufacturing
- Leveraging technology and digital transformation to digitize aspects of your facility: AI infused employee experiences, constraint-based automation, etc.
- How Gilead is taking digital and unique persona-based approaches to reformulate the way we work
- Prioritizing digital transformations now to be ready for the next disruption

BIOMANUFACTURING 4.0 - HOW TO GET THERE?

- What is the significance of new technology innovation in Merck Group's operations?
- Examining the global manufacturing and supply network for areas of opportunity and current growth
- How to best onboard and train employees to tech-savvy operations
- Discussing examples of technology that have improved manufacturing and supply teams

11:45 am – 12:25 pm EST

PRE-ARRANGED 1-2-1 BUSINESS MEETINGS AND NETWORKING

12:30 pm – 1:05 pm EST

SESSIONS

MANUFACTURING AND TECHNOLOGY

ASHLEY GROVES
Principal Process Engineer, Cell Culture Technical Transfer and Production Support
Sanofi

LEVERAGING QBD PRINCIPLES WITH PLATFORM DEFINITIONS FOR A MORE AGILE CLINICAL MANUFACTURING

- Reduced time and resources to initiate GMP manufacturing
- Clarify expectations for sending and receiving units with established platform definitions
- Increase confidence in program success by leveraging QbD principles
- Create and maintain templates for increased plant and development consistency
- Establish a continuous learning and improvement environment

QUALITY AND COMPLIANCE

LISA WYMAN
SVP, Technical Operations and Quality
Acceleron Pharma Inc.

LEVERAGING RESILIENCE AND REINVENTION TO ADVANCE BIOPHARMACEUTICAL QUALITY

- What is the future of biopharmaceutical quality and compliance and how do we get there?
- Generating competitive advantage using the principles of resilience and learning agility
- Evolving current quality practices to be more efficient and agile without compromising product quality or supply continuity

SUPPLY CHAIN AND LOGISTICS

CHRISTOPH PISTEK, PH.D.
Head, Technology Sciences, R&D, Pharmaceutical Sciences
Takeda

ACCELERATING PIPELINE PROGRESSION: CHALLENGES AND OPPORTUNITIES OF BIOPROCESSING 4.0 IN PROCESS DEVELOPMENT

- How can Bioprocessing 4.0 be a greater enabler of faster global access to therapies?
- Reviewing Industry 4.0 principles, methods and computational technologies can help to speed up the delivery of a modality-diverse pipeline
- Discussing emerging technologies that can be applied from early development on
- Achieving transformational, end-to-end innovation in commercial manufacturing
- Onboarding new capabilities while mitigating risk to development pathways

1:10 pm – 1:50 pm EST

LUNCH & LEARN ROUNDTABLE DISCUSSIONS

Benefit from additional learning by joining a moderated roundtable discussion on pressing issues in the industry. Registration is required and attendance is limited. Choose from:

BRUNO MARQUES
Senior Director and Head, Process and Product Development
Century Therapeutics

EXPLORING AVENUES TO ADAPT AUTOLOGOUS SUPPLY CHAINS TO ALLOGENEIC PRODUCTS

GEOFFREY POT
Site Head and VP, Operations
Takeda

DISCUSSING THE BENEFITS OF IMPLEMENTING DIGITALIZED BIOMANUFACTURING OPERATIONS

SUSANNE ROMMEL, PH.D., MBA
Executive Director, Development and Commercial Quality
Gilead Sciences

SMALL STRATEGIES TO FOSTER AN INNOVATIVE QMS ACROSS THE PORTFOLIO

DIANE WILKINSON, PH.D.
Senior Director, Regulatory CMC, Global Regulatory Excellence
AstraZeneca

DEVELOPING VACCINES AND WORKING WITH AGENCIES FOR GLOBAL APPROVAL

RUBY CASARENO, PH.D.
SVP, Technical Operations
Allakos, Inc.

LEVERAGING RESILIENCE AND REINVENTION TO ADVANCE BIOPHARMACEUTICAL QUALITY AMIDST COVID-19 PRESSURES

PAT HANCOCK
Executive Director, Global Quality Systems and Operations
Genentech, A Member of the Roche Group

HOW DO YOU BUILD YOUR QUALITY CULTURE?

1:55 pm – 2:30 pm EST

WORKSHOPS

MANUFACTURING AND TECHNOLOGY

LARS SÖDING
Principal, Production IT Software
Körber Pharma

CLÉMENTINE TASSAUX
Associate Principal, Production IT
Körber Pharma

DRIVING DIGITAL TRANSFORMATION IN BOTH PHARMA AND BIOTECH: ACCELERATE YOUR DIGITAL JOURNEY

- Overviewing how the global pandemic has forced many businesses around the globe to fast track their digitization transformation initiatives
- Even though the future seems obscure, one thing is clear: digital advancement is unavoidable
- How organizations are undertaking activities focused on the key steps needed to ensure business continuity and resilience
- Why successful digital transformation initiatives bring exceptional values to organizations

QUALITY AND COMPLIANCE

KEITH DODSON
VP, Global Business Development
AST

QUALITY FIRST: REINVENTING YOUR ASEPTIC PROCESSING WITH FLEXIBLE ROBOTIC MANUFACTURING

- Addressing and responding to the fill-finish challenges of your biologic product
- Discussing the advantages of robotics in aseptic fill finish for complex biotech manufacturing processes
- What options are there to ensure your aseptic processing and equipment manufacturing are placing quality at the forefront?
- Highlighting the importance of maintaining quality aseptic conditions throughout the production process

SUPPLY CHAIN AND LOGISTICS

BUILDING GENE THERAPY SUPPLY CHAINS OF THE FUTURE

- Understanding the unique challenges in launching an FDA approved gene therapy
- Discussing emerging technologies to support innovative and individualized product supply strategies
- What best practices can we borrow from current pharma supply chains?
- Exploring challenges for managing gene therapy supply chain risks

2:35 pm – 3:15 pm EST

PANEL DISCUSSION

MICHAEL MULLETTE
VP, North America Commercial Operations
Moderna

ANISSA BOUMLIC
Director, Bioprocessing Strategy Operationalization
MilliporeSigma

PHILIP DORMITZER
VP and Chief Scientific Officer, Viral Vaccines, Pfizer Vaccines Research and Development
Pfizer, Inc.

BOB DI SCIPIO
CEO
Skyland Analytics

MANOJ MENON
Senior Director, Global Drug Substance Manufacturing Network
AstraZeneca

TONY D'AMORE, PH.D.
VP, Product Research and Development
Sanofi Pasteur

DEVELOPING VACCINES AT PANDEMIC SPEED

- Examining the need to rapidly develop vaccines
- What tools and technologies can support a new era in vaccine development?
- How the vaccine industry have been asked to respond urgently to epidemics
- Working in tandem with the regulatory agencies to accelerate the process
- Utilizing novel platforms and next-generation sequencing technologies
- Meeting the demand for vaccines around the world

3:20 pm – 3:25 pm EST

CLOSING REMARKS & PRIZE ANNOUNCEMENTS

3:25 pm – 4:25 pm EST

EXPO HALL NETWORKING